Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection licensed in Great Britain for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea, as an adjunct to diet and physical activity
In the pancreas, GLP1 receptor activation augments glucosedependent insulin secretion and suppresses inappropriate glucagon secretion, thereby improving postprandial glycemia without a high intrinsic risk of hypoglycemia in the absence of concomitant insulin or secretagogues
This will help give your body a chance to get used to the medicine
This means that the patent will expire on March 20, 2026.
The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis
doi: 10.1186/s12944-017-0609-0 33 PastelEMcCullochLJWardRJoshiSGoodingKMShoreACet al
